Mechanism of Action
Regarding its mechanism of action, doxycycline is a protein translation inhibitor. The drug penetrates the pathogen cell and blocks protein synthesis, which halts the growth and reproduction of the infectious agent.
This mechanism applies not only to bacteria but also to protozoa. In the pharmacological classification of antimalarial agents based on mechanism of action, antibiotics (including doxycycline, tetracycline, and clindamycin) are designated as a separate group of drugs that inhibit protein translation in Plasmodium.
Pharmacokinetics and Safety Profile
The pharmacokinetics of doxycycline have fundamental differences compared to other members of the tetracycline group, which determines its high safety profile:
- Route of Elimination: Unlike other tetracyclines, the drug is excreted to a minimal degree via the kidneys. The primary route of elimination is predominantly through the feces.
- Safety in Renal Impairment: Since the drug does not place a pharmacological burden on the renal system, it is safe and suitable for patients with concurrent renal failure.
- Effect on Microbiota: In the intestine, the drug is present mainly in an inactive form. Consequently, it has minimal impact on the normal gut flora.
- Side Effects: Compared to classic tetracyclines, doxycycline significantly less often causes nausea, vomiting, and superinfections. This property makes it an especially important drug of choice for immunocompromised patients.
Indications for Use
Doxycycline possesses a specific spectrum of activity and is used for several severe, atypical, and highly dangerous infections.
1. Antimalarial Therapy
In the clinical classification of antimalarial agents, the drug belongs to two categories:
- Erythrocytic stage treatment (erythrocytic schizonticides): The targets are the erythrocytic forms of plasmodia. The drug is used to relieve clinical manifestations, particularly as part of combination chemotherapy for falciparum malaria (Plasmodium falciparum), especially in chloroquine-resistant strains.
- Individual chemoprophylaxis: The targets are pre-erythrocytic and erythrocytic forms. The goal is to prevent disease development in an individual. It can be used either as monotherapy or in combination (e.g., Atovaquone + doxycycline).
2. Highly Dangerous and Zoonotic Infections
- Plague (Yersinia pestis): used in combination with streptomycin.
- Cholera (Vibrio cholerae): used alongside ciprofloxacin.
- Brucellosis (Brucella): prescribed in combination with rifampin (streptomycin may also be used in brucellosis).
3. Infections Caused by Spirochetes
- Lyme disease (Borrelia burgdorferi): serves as one of the primary treatment medications.
4. Intracellular and Atypical Pathogens
- Rickettsial infections (Rickettsiae): the drug of choice for epidemic typhus, Rocky Mountain spotted fever, and Q fever.
- Chlamydial infections (Chlamydia): used alongside azithromycin.
- Mycoplasma infection (Mycoplasma pneumoniae): used alongside macrolides.
Dosage Forms and Administration Guidelines
According to reference formularies, doxycycline (Doxycycline hydrochloridum) is available in several dosage forms for enteral and parenteral administration:
- Ampoules: 0.1 g.
- Capsules: 0.05 g and 0.1 g.
- Coated tablets: 0.1 g.
- Syrup: in 20 ml bottles (concentration of 0.01 g of doxycycline per 1 ml).
Dosing Regimen:
- Oral (enteral): 0.1–0.2 g once daily.
- Intravenous (infusion): the dose is 0.1 g.
- Reconstitution rule: The contents of the ampoule must first be dissolved in 10 ml of sterile water for injection. The resulting solution is then diluted in 250 ml of 5% glucose solution.
- Infusion rate: Administer via intravenous drip strictly over 1 hour.